Shreya Ramesh Advances in International Competition Against Top Students 

Atlanta, GA (April 6, 2020)  – Georgia Bio and the Georgia BioEd Institute today named  Shreya Ramesh , a senior at Milton High School in Milton, GA, as the winner of the 2020 Georgia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field.  As Georgia’s BioGENEius finalist, Shreya will attend the 2020 International BioGENEius competition, which will be held virtually during the BIO Digital Convention.

Shreya will compete against high school students from the U.S., Canada and Germany in the International BioGENEius Challenge. The student projects will represent a range of biotechnology topics such as healthcare, agriculture, and the environment.

Shreya Ramesh headshot
Shreya Ramesh, 2020 Georgia BioGENEius Challenge Winer

Shreya’s award-winning research uses machine learning to assess the voice features of Amyotrophic Lateral Sclerosis (ALS) patients. The voices of ALS patients are characteristically slower, higher pitched, and softer than the voices of individuals who do not have ALS. Using ALS voice feature data, Shreya created a voice compensation algorithm to convert the ALS patient’s voice into one more similar to a non-ALS patient. This allowed the ALS patient’s voice to be better recognized by Automatic Speech Recognition (ARS) programs like Google Voice or Amazon’s Alexa. ALS patients often rely on ARS programs due to their limited mobility, but their voice features are not recognized by these programs.

“The BioGENEius Challenge highlights the breakthroughs made when we invest in and encourage young people to pursue their ideas,” said Georgia Bio President and CEO Maria Thacker. “Georgia Bio is thrilled that Shreya will represent our state at the upcoming BIO Convention. We are proud to support this Georgia scholar as she develops tomorrow’s healthcare innovations.”

Georgia Bio also congratulates the Georgia BioGENEius runner-up,  Krish Wadhwani  of Denmark High School in Alpharetta, GA. Krish’s project focused on the production of synthetic antibody mimics (SyAMs) as treatment for Huntington’s disease (HD) and Alzheimer’s Disease (AD). The SyAMs are engineered antibodies that can bind to the misshapen proteins responsible for causing symptoms in HD and AD. This would inhibit the proteins and help control symptoms of the disease. Krish plans to continue this research and next hopes to get funding to pursue clinical production and testing of the antibodies. 

Krish Wadhwani headshot
Krish Wadhwani, 2020 Georgia BioGENEius Challenge Runner-Up

Judging the 2020 Georgia BioGENEius were Jamie L. Graham, Kilpatrick Townsend & Stockton; Ralph L. Cordell, CDC; and Ian Biggs, UGA.

National and International winners will be announced after the competition. See the  International BioGENEius website  for more information on the revised 2020 schedule. Winners will receive cash scholarships.

# # #

Follow the BioGENEius Challenge:  Throughout the challenge, @BiotechInstitut will be tweeting interviews, photos, and engaging with the biotechnology community by using the hashtag #BioGENEius.

About the Biotechnology Institute

The Biotechnology Institute is an independent, national nonprofit organization dedicated to education about the present and future impact of biotechnology.  Its mission is to engage, excite and educate the public, particularly students and teachers, about biotechnology and its immense potential for solving human health, food and environmental problems.  For more information, visit www.biotechinstitute.org.

About the GeorgiaBioEd Institute 
The Georgia BioEd Institute is a division of Georgia Bio, a 501(c)(3) nonprofit organization serving the state’s life science industry. The Institute’s mission is to strengthen Georgia’s life sciences workforce pipeline through classroom-to-career initiatives that align with industry needs. Learn more at  www.georgiabioed.org  |  www.gabio.org.

MEDIA CONTACT : 

Maria Thacker
404-920-2042
mthacker@gabio.org

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: